Evan Lee Salim
In the realm of speculative science, few companies have captured the public imagination—or the skepticism of the scientific community—quite like Colossal Biosciences. What began as a headline-grabbing mission to "resurrect" the woolly mammoth has rapidly mutated into a diversified deep-tech powerhouse. According to recent reports, the five-year-old Dallas-based startup is currently in talks to secure a fresh injection of capital that could catapult its valuation into the stratosphere, reaching between $20 billion and $30 billion.
This potential funding milestone, first reported by Axios, marks a staggering ascent for a company that was, until recently, viewed by many as a venture-backed fantasy. While the ethics of de-extinction remain a subject of intense academic debate, the market is clearly betting on the proprietary technologies Colossal is developing along the way.
The Evolution of a Scientific Moonshot
Founded on the audacious premise of bringing extinct species back from the brink of history, Colossal Biosciences has spent the last 16 months pivoting from a pure-play biology firm to an integrated technology ecosystem. The company, led by co-founder and CEO Ben Lamm, is no longer just chasing mammoths; it is building a suite of patents and platforms that have far-reaching implications for human health, environmental remediation, and agricultural sustainability.
The latest funding round—the specifics of which, including the lead investor and total capital sought, remain under wraps—suggests that investors are looking past the "Jurassic Park" headlines. They are instead focusing on the tangible, revenue-generating entities that Colossal has successfully incubated.
A Chronology of Innovation and Expansion
- 2021: Colossal Biosciences is founded with the goal of using CRISPR and advanced genetic engineering to de-extinct the woolly mammoth.
- 2023: The company announces its intent to resurrect the dire wolf, signaling a shift toward a broader "de-extinction portfolio."
- 2024: Colossal formalizes its conservation arm, the Colossal Foundation, and begins securing high-level government partnerships.
- 2025 (January): The startup raises $200 million, cementing a $10.2 billion valuation.
- 2026 (March): The spin-out company Astromech reaches a $2 billion valuation, highlighting the success of the company’s "venture studio" model.
- 2026 (April): The bluebuck antelope is added as the company’s sixth target species for revival.
- 2026 (July): Reports surface of a new fundraising round targeting a $20 billion to $30 billion valuation as the company moves into commercial revenue generation.
Diversification: The Secret to the $30 Billion Valuation
The shift in valuation—from $10 billion to potentially $30 billion in just over a year—is largely attributed to the company’s success in commercializing its core research. Colossal has effectively deployed a venture studio model, spinning out independent entities that leverage the foundational science developed in its 55,000-square-foot Dallas headquarters.
Key Subsidiary Developments
- Breaking: A biotech firm focused on plastic degradation, utilizing engineered enzymes to tackle the global crisis of microplastics.
- Form Bio: A computational biology platform that has secured $30 million in funding. It serves as the "picks and shovels" for the modern biotech era, providing software solutions for complex genomic modeling.
- Astromech: An AI-driven predictive modeling company. Valued at $2 billion as of March 2026, it represents the intersection of machine learning and life sciences, focusing on biological outcomes that were previously impossible to predict.
By diversifying into these sectors, Colossal has de-risked its business model. While the resurrection of a dodo bird is a long-term, high-risk endeavor, the software and environmental solutions provided by Form Bio and Breaking offer immediate, scalable utility in existing markets.
Government Partnerships and Institutional Validation
Perhaps the most significant signal of the company’s legitimacy is the willingness of sovereign entities to back its research. Earlier this year, the UAE invested $60 million in the company, a move that underscores the strategic value of Colossal’s conservation technology. Furthermore, the company has begun working with the U.S. government on initiatives related to endangered species recovery, suggesting that the U.S. Department of the Interior sees tangible value in the genetic tools Colossal is refining.
The Colossal Foundation, the company’s nonprofit wing, has also made waves. Its recent partnership with the University of Tasmania to combat "devil facial tumour disease" (DFTD)—a transmissible cancer threatening the Tasmanian devil—demonstrates a commitment to applied, real-world conservation that transcends the "de-extinction" label. By using gene editing to boost natural immunity in existing species, Colossal is positioning itself as a leader in global biodiversity management.
The Future of Revenue: Biodiversity and Human Health
When questioned about the sustainability of such a high valuation, CEO Ben Lamm has consistently pointed toward three distinct revenue streams: government contracts, the monetization of spin-off technologies, and the future market for biodiversity credits.
The concept of "biodiversity credits" is gaining traction among environmental economists. Much like the carbon credit market, this system would allow corporations to purchase credits to offset their environmental footprint by funding the restoration of keystone species into native habitats. If Colossal succeeds in its goal of reintroducing the woolly mammoth to the Arctic, it could potentially unlock a massive market for these credits, as the rewilding of such species is theorized to play a significant role in carbon sequestration and ecosystem stability.
Furthermore, the company’s foray into human-adjacent technologies—specifically its "artificial animal womb" project—is a potential game-changer. While currently designed for animal applications, the technology has obvious and lucrative implications for human fertility treatments and neonatal care. Lamm indicated to Rolling Stone earlier this year that this technology is nearing a state of operational readiness, slated for as early as next year.
Implications and Challenges
Despite the astronomical numbers, the road ahead is not without obstacles. The scientific community remains divided on the long-term feasibility of de-extinction. Critics argue that diverting resources toward resurrecting long-gone species ignores the urgent need to protect the millions of species currently facing extinction due to human activity and climate change.
Moreover, the regulatory landscape for genetic engineering is notoriously complex. As Colossal moves closer to its goal of reintroduction, it will face intense scrutiny from international bodies regarding the ethical implications of "playing God" and the potential for ecological disruption.
From a financial perspective, a $30 billion valuation puts Colossal in the "decacorn" tier of private companies, placing immense pressure on the leadership team to deliver on long-promised technological milestones. The company has not responded to requests for comment regarding the latest funding reports, but silence is common during sensitive financial negotiations.
Conclusion: A New Era of Deep-Tech
Colossal Biosciences is a mirror of the modern age: a synthesis of extreme biological ambition, AI-driven computational power, and a desperate global need for environmental innovation. Whether or not they succeed in walking a living, breathing woolly mammoth through the doors of their Dallas headquarters, the company has already achieved something profound. They have successfully institutionalized the field of de-extinction, turning a scientific pipe dream into a multi-billion dollar engine for technological progress.
As the company prepares for this next phase of growth, the global community watches with a mix of awe and trepidation. If the valuation holds, it will mark one of the most significant moments in the history of biotech—an acknowledgment that the tools of the future will be built not just by writing code, but by editing the very blueprint of life itself.
Azzam Bilal Chamdy
Asro
